GlassScriptPhysician profile
Brian M Karaszewski
NPI 1255478376
$27,538.19
in general payments reported to CMS, 2019-2025
70 companies · $4,057 in 2025
The $4,057 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,088 · 2020: $3,412 · 2021: $4,190 · 2022: $3,481 · 2023: $4,077 · 2024: $4,235 · 2025: $4,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $36.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,332.30 |
| Education | $36.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,015.78 | 2019-2025 | Jardiance, Spiriva Respimat, Ofev |
| Abbvie INC. | $2,683.99 | 2019-2025 | |
| Lilly USA, LLC | $2,414.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $2,144.49 | 2019-2025 | Trelegy Ellipta, Benlysta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,043.72 | 2019-2025 | Saphnelo, Farxiga, Breztri |
| Amgen INC. | $1,912.28 | 2019-2025 | Otezla, Tavneos, Repatha |
| Pfizer INC. | $1,192.15 | 2019-2025 | |
| Novo Nordisk INC | $1,008.18 | 2019-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $1,001.36 | 2019-2025 | Trintellix, Cuvitru, Eohilia |
| Ucb, INC. | $760.35 | 2019-2025 | Bimzelx, Cimzia |
| Astellas Pharma US INC | $752.42 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $604.49 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $585.05 | 2019-2025 | Verquvo, Belsomra, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $539.82 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $467.04 | 2019-2023 | Seglentis, Livalo |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Karaszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.